Cilostazol controlled-release - Korea United Pharma

Drug Profile

Cilostazol controlled-release - Korea United Pharma

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Korea United Pharm Inc
  • Class Antiplatelets; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Arterial occlusive disorders; Intermittent claudication

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Arterial-occlusive-disorders(In volunteers) in South Korea (PO, Controlled release)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Intermittent-claudication(In volunteers) in South Korea (PO, Controlled release)
  • 09 Mar 2013 Phase-I clinical trials in Arterial occlusive disorders (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top